You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back


This is the same number of viral replication sites as typical three drug regimens – without the need for TDF, TAF and ABC.3-5

DTG and 3TC block two separate sites of the viral replication cycle – the same number as most 3 drug regimens (which typically contain 3 drugs from two classes).*,3,6-9 This makes it difficult for the virus to develop mutations that confer treatment resistance.8,9

Lamivudine (3TC) disrupts HIV from transcribing its RNA into DNA inside the CD4 cell, by blocking the activity of reverse transcriptase.3

Dolutegravir (DTG) disables the activity of HIV integrase, thereby preventing the integration of viral DNA into the host cell’s DNA.3

CD4 Cell illustration

*most NRTI-based 3DRs.


…enabling DOVATO to remain at effective concentrations for ~84 hours post dose.10 this, alongside the once-daily dosing interval3, help to support the high barrier to resistance of DOVATO.

The pharmacokinetic profiles of DTG and 3TC are synchronised – Both remain at effective concentrations ~84 hours post-dose.3,10,11 This, and the once-daily dosing interval, help to support the high barrier to resistance of DOVATO.3,10

Antiretrovirals with a long half-life help to provide sustained exposure of HIV to treatment; ARV's with a longer half-life suggests sustained exposure beyond the dosing interval –contributing to a high barrier to resistance.10,12

PK Profiles Graph


A Dynamic Duo with a proven high barrier to resistance and low rates of treatment emergent resistance.1,2,13,16,17

Low rates of treatment-emergent resistance have been reported which is similar to 2nd generation INSTIs in 3DR regimens.16,18-21

This clinical and real-world data illustrates the strength of the two agents in DOVATO and their ability to provide a high barrier to resistance.

Graph outlining the low rates of treatment emergent resistance with Dovato


TDF = tenofovir disoproxil fumarate; TAF = tenofovir alafenamide; ABC = abacavir; DTG = dolutegravir; RNA = ribonucleic acid; DNA = deoxyribonucleic acid; HIV = human immunodeficiency virus; CD4 = clusters of differentiation 4; 3TC = lamivudine; PLHIV = people living with HIV; TP = triphosphate; BID = twice daily; PA-IC90 = protein-adjusted 90% inhibitory concentration; PK = pharmacokinetic; QD = once daily.


  1. Google. Oxford Languages 2023. Dynamic dictionary definition. Available at: Accessed January 2024.
  2. GlaxoSmithKline. Fuelling Our Future Growth 2023. Available at: Accessed July 2023.
  3. Dovato. Summary of Product Characteristics. January 2024. Available at:
  4. European AIDS Clinical Society (EACS) Guidelines. Version 12.0 October 2023.
  5. Aquaro S et al. Virulence 2020; 11(1): 400–413.
  6. Tseng A et al. Br J Clin Pharmacol. 2014; 79(2): 182–194.
  7. Feng Q et al. BMJ 2019; 366: l4179
  8. Rousseau F et al. J Infect Dis 2003; 188(11): 1652–1658
  9. Perelson A et al. Science. 1996; 271(5255): 1582–1586
  10. Boffito M et al. AIDS Res Hum Retroviruses 2020; 36(1): 13 18.
  11. Min S et al. Antimicrob Agents Chemother 2010; 54(1): 254 258.
  12. Viswanathan S et al. AIDS Behav 2015; 19: 601–11.
  13. Cahn P et al. AIDS 2022; 36(1): 39–48;
  14. Maggiolo F et al. BMC Infect Dis 2022; 22(1): 782.
  15. Ciccullo A, Borghi V, Giacomelli A, et al. Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding. J Acquir Immune Defic Syndr. 2021;88(3):234-237.
  16. Cabello-Ubeda A 2022. PLoS ONE; 17: 1 11.
  17. Mendoza I, Lázaro A, Torralba M. Effectiveness, durability, and safety of dolutegravir and lamivudine versus dolutegravir, lamivudine, and abacavir in a real-life cohort of HIV-infected adults. Ann Pharmacother. 2022;56(4):412-421. doi:10.1177/10600280211034176
  18. Gagliardini R et al. JGAR 2022; 28: 274 – 281.
  19. Calza L, Colangeli V, Borderi M, et al. Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy. J Antimicrob Chemother. 2020;75(11):3327-3333. doi:10.1093/jac/dkaa319
  20. Nasreddine R et al. HIV Med 2022; 1–12.
  21. Scholten S et al. Poster presented at the 18th European AIDS Conference. 27–30 October 2021. London, England. PE2/52.
  22. De Wit S et al. Slides presented at HIV Glasgow 2022. 23–28 October 2022. Glasgow, United Kingdom. MO41.
  23. Llibre J et al. Clin Infect Dis 2023; 720–729.
  24. Rolle C et al. AIDS 2021; 35(12): 1957–1965.
  25. Ciccullo A, Baldin G, Dusina A, et al. Efficacy and safety of dolutegravir plus lamivudine as a first-line regimen in clinical practice. AIDS Res Hum Retroviruses. 2021;37(6):486-488. doi:10.1089/AID.2020.0276
  26. Amor García MA, Rodríguez-González CG, Chamorro-de-Vega E, Herranz-Alonso A, Sanjurjo-Sáez M. Dolutegravir-based dual therapies in HIV pretreated patients: a real-life study in Madrid. Ann Pharmacother. 2022;56(4):401-411. doi:10.1177/10600280211038504
  27. Hidalgo-Tenorio C, Pasquau J, Vinuesa D, et al. DOLAVI real-life study of dolutegravir plus lamivudine in naive HIV-1 patients (48 Weeks). Viruses. 2022;14(3):524. doi:10.3390/v14030524.
  28. Lanzafame M, Nicole S, Rizzardo S, et al. Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1 infected patients deintensificated from abacavir/lamivudine/dolutegravir to lamivudine plus dolutegravir. New Microbiol. 2018;41(4):262-267.
  29. Malagnino V, Teti E, Compagno M, et al. HBcAb positivity is a risk factor for an increased detectability of HIV RNA after switching to a two-drug regimen lamivudine-based (2DR-3TC-based) treatment: analysis of a multicenter Italian cohort. Microorganisms. 2021;9(2):396. doi:10.3390/microorganisms9020396
  30. Tan M, Johnston S, Nicholls J, Gompels M. Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients? HIV Medicine. 2019;20: 634-637. doi:10.1111/hiv.12781
  31. Krentz H, Campbell S, Lahl M, Gill MJ. Uptake success and cost savings from switching to a two-drug antiretroviral regimen. AIDS Pat Car and STDs. 2022;36(1):1-7. doi:10.1089/apc.2021.0118
  32. Ruiz-Algueró M, Hernando V, Riero M, et al. Temporal trends and geographic variability in the prescription of antiretroviral treatments in people living with HIV in Spain, 2004-2020. J Clin Med. 2022;11:1896. doi:10.3390/jcm11071896
  33. Maggiolo F et al. Poster presented at the 11th International AIDS Society Conference on HIV Science. 18-21 July 2021. Virtual. PEB179.
  34. Rolle C-P, Berhe M, Singh T, et al. High rates of virologic suppression with DTG/3TC in newly diagnosed adults with HIV-1 infection and baseline viral load ≥500,000 c/mL: 48-week subgroup analysis of the STAT study. Presented at: IDWeek 2021; September 29-October 3, 2021; Virtual.
  35. Llibre JM, Alves Brites C, Cheng CY, et al. Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination is non-inferior to continuing a 3-drug regimen through 48 weeks in a randomized clinical trial (SALSA). Presented at: The 11th International AIDS Society Conference on HIV Science; July 18-21, 2021; Virtual. Slides OALB030.
  36. Alves Correia RM, Carvalho AC. Real life study with dual therapy in a HIV-1 treatment experienced Portuguese Cohort. Presented at: The 23rd International AIDS Conference; July 6-10, 2020. Virtual. Poster PEB0235.
  37. Bowman C, Ambrose A, Simons P, et al. Performance of dolutegravir based two drug regimens (DTG-2DR) in a large real-world cohort of people with HIV. Presented at: The British HIV Association Spring Conference 2022; April 20-22, 2022. Manchester, United Kingdom. Poster.
  38. Bravo O, Martínez E, Martínez-Alfaro C, et al. P-145. Multi-central study to evaluate effectiveness and safety of the dolutegravir and lamivudine biterapy in vida real. 2019. Abstract.
  39. Cabello A, López Bernaldo de Quiros JC, Pulido F, et al. 48 weeks efficacy and tolerability of dolutegravir (DTG) + lamivudine (3TC) in adult HIV naïve patients: a multicenter real life cohort. Presented at: The 11th International AIDS Society Conference on HIV Science; July 18-21, 2021; Virtual.
  40. Calza L, Legnani G, Fulgaro C, et al. Changes in serum inflammatory markers in antiretroviral therapy–naive HIV-infected patients starting dolutegravir/lamivudine or dolutegravir/lamivudine/abacavir. J Acquir Immune Defic Syndr. 2022;89:e30. doi:10.1097/QAI.0000000000002861
  41. Cucchetto G, Lanzafame M, Nicolé S, et al. Integrase inhibitors with lamivudine, as maintenance-dual therapy, in a real-life clinical settings. Presented at: The Italian Conference on AIDS and Retroviruses, June 6-8 2016, Milan, Italy. P69.
  42. Dou Y, Li Y, Hong Z, et al. The efficacy of DTG+3TC in naïve patients–The real world data from southern China. Presented at: EACS 2021. Poster PE2-19.
  43. Fernández Zamora C, Rodriguez Martinez T, Merono Saura MA, et al. Effectiveness of dolutegravir and lamivudine therapy in a two drug regimen in a third level hospital. Eur J Hosp Pharm. 2020;27(suppl 1):A79. doi:10.1136/ejhpharm-2020-eahpconf.169
  44. Gagliardini R, Lorenzini P, Cozzi-Lepri A, et al; for the Icona Foundation Study Group. Effect of past virological failure on dolutegravir + lamivudine as maintenance regimen. Presented at: Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, MA. Poster 0486.
  45. Galizzi N, Poli A, Galli L, et al. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. Int J Ant Agent. March 2020;55(54)1-8. doi:10.1016/j.ijantimicag.2020.105893
  46. Gianotti N, Tavell A, Antinori A, et al. Are patients starting first-line ART with a 2-drug regimen (2DR) with dolutegravir/lamivudine different from those initiating 3-drug regimens (3DR) based on an integrase strand transfer inhibitor (InSTI), plus tenofovir alafenamide/emtricitabine. Presented at: The 11th IAS Conference on HIV Science; July 18-21, 2021. Poster A-IAS2021-00429.
  47. Haidari G, Barchi W, Chilton D, Kulasegaram R. Dolutegravir/lamivudine (DTG/3TC) in people living with HIV (PLWH) as a switch or start: a London based experience. Presented at: The 18th European AIDS conference, October 27-30th, 2021. London, United Kingdom.
  48. Hiryak K, Kludjian G, Samuel R, et al. Real-world implementation of dolutegravir-lamivudine to achieve and maintain HIV-1 viral suppression at an academic medical center. Presented at: ID Week; October 21-25, 2020; Virtual.
  49. Hocqueloux L, Allavena C, Secher S, et al. Archived mutation M184V does not increase virologic failure during maintenance therapy with dolutegravir + lamivudine in the French DAT’AIDS cohort. Presented at: 18th European AIDS Conference, October 27-30, 2021. Poster OS1-2.
  50. Pasqua Liaño J, Sequera Arquelladas S, López-Cortez, et al. DOLAM study 200: effectiveness safety and economic evaluation of a dual therapy with dolutegravir plus lamivudine in treatment-experienced HIV patients. Presented at: The 18th European AIDS conference, October 27-30th, 2021. London, United Kingdom. Poster PE2-38.
  51. Ma J, Nance RM, Delaney JAC, et al. Current antiretroviral treatment among people with HIV in the US: findings from the CNICS cohort. J Clin Inf Dis. 2022;1-15. doi:10.1093/cid/ciac086
  52. Nasreddine R, Yombi JC, Darcis G, et al. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium. 2022. Poster.
  53. Noe S, Jonsson-Oldenbuettel C, Heldwein S, et al. High persistence of dolutegravir-containing 2-drug regimens in real life. Presented at: 17th European AIDS Conference. 2019.
  54. Pereira Goulart S, de Albuquerque Moras C, Furtado da Costa A, et al. ART simplification: use of dual therapy for HIV in a public health reference center (CRT-DST/Aids) in São Paulo, Brazil. Presented at: 17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland. Poster PE2/34.
  55. Pierone G, Brunet L, Fusco JS, et al. Switching to dolutegravir/lamivudine two-drug regimen: durability and virologic outcomes in routine U.S. clinical care. Presented at: The 24th International AIDS Conference; July 29-August 2, 2022; Montreal, Canada. Poster.
  56. Povar-Echeverría M, Comet-Bernad M, Gasso-Sánchez A, et al. Neuropsychiatric adverse effects of dolutegravir in real-life clinical practice. Enferm Infecc Microbiol Clin. 2021;39(2):78-82. doi:10.1016/j.eimc.2020.02.018
  57. Rodríguez Alonso B, Úbeda C, Bonilla M, et al. P203 efficacy and tolerance of dolutegravir-based bitherapy (DTG) in simplification outside clinical trials. Presented at: GeSIDA 2017. Poster P203.
  58. Santoro MM, Armenia D, Teyssou E, et al. Impact of M184V on the virological efficacy of switch to 3TC/DTG in real life. Presented at: CROI 2021. Poster.
  59. Schneider S, Burke C, Ward D, et al. Treatment experience of single-tablet dolutegravir/lamivudine in the United States: results from the real-world outcomes with dolutegravir-based two-drug-regimens Dovato and Juluca for the treatment of HIV-1 (TANDEM study). Presented at: The 24th International AIDS Conference; July 29-August 2, 2022; Montreal, Canada. Poster EPB147.
  60. Scholten S, Noe S, Wyen C, et al. 12-month outcomes of dolutegravir (DTG) + lamivudine (3TC) in ART-naïve and pre-treated people living with HIV in Germany: real-world data from the German URBAN cohort. Presented at: The 18th European AIDS Conference, October 27-30, 2021. London, United Kingdom. Poster PE2-52.
  61. Silva Sombra, Loiola MM, Vasconcelo M, et al. Simplification with lamivudine/dolutegravir dual therapy in HIV patients with real-life virological suppression (LAMDO study). Braz J Infect Dis. 2021;25:(S1). Abstract.
  62. Stephenson L, Pan D. Clinical experience of dolutegravir + lamivudine dual treatment regimens at University Hospital Leicester NHS Trust. Presented at: 26th Annual Conference of the British HIV Association; November 22-24, 2020; Virtual.
  63. Taramasso L, De Vito A, Ricci ED, et al. Durability of dolutegravir-based regimens: a 5-year prospective observational study. AIDS Patient Care STDs. 2021;35(9):342-353. doi:10.1089/apc.2021.0089
  64. Teira R, Diaz-Cuervo H, Aragão F, et al. Shorter time to treatment failure in people living with HIV switched to dolutegravir plus either rilpivirine or lamivudine compared to integrase inhibitor-based triple therapy in a large Spanish cohort (VACH). Presented at: 26th Annual Conference of the British HIV Association; November 22-24, 2020; Virtual. Poster P031.
  65. Uriel AJ, Banks T, Ashton K, et al. Dual antiretroviral (ARV) therapy: safe and efficacious even in a heavily ARV experienced real-world cohort. Presented at: 26th Annual Conference of the British HIV Association; November 22-24, 2020; Virtual.
  66. Vergas TJ, Estrada J, Perez-Somarriba J, et al. P-190. Bitherapies without protease inhibitors. a safe and efficient option. Presented at: GeSIDA 2017.
  67. Yagci-Caglayik D, Gokengin D, Inan A, et al. Real life experience of dolutegravir and lamivudine dual therapy as a switching regimen in HIVTR cohort. Presented at: The 16th European AIDS conference; October 25-27, 2017. Milan, Italy.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.

Date of preparation: February 2024 | PM-IE-DLL-WCNT-230004